SEC Filing Summary: Ra Medical Systems, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Ra Medical Systems, Inc. (RMED) on August 12, 2019, covering events occurring on August 11 and 12, 2019. The filing addresses significant management changes, the initiation of an independent investigation, and the delay of the Company's Form 10-Q for the quarter ended June 30, 2019.
Key Financial Metrics
The filing references preliminary financial results for the three months ended June 30, 2019, which were announced in a press release attached as Exhibit 99.1. However, this specific 8-K text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The Company stated it cannot file its Form 10-Q until the ongoing Audit Committee investigation is completed.
Material Changes and Management Actions
- CEO Termination: Dean Irwin was terminated as Chief Executive Officer, Co-President, and Chief Technology Officer effective August 12, 2019. The termination was without "Cause." Mr. Irwin remains on the Board of Directors and is eligible for severance benefits.
- Leadership Appointment: Andrew Jackson, the Company's Chief Financial Officer, was appointed as Interim Chief Executive Officer and Principal Executive Officer effective August 12, 2019. He will receive an additional stipend of $6,000 per month while serving in this interim role.
- Board Changes: Martin Colombatto was appointed Chairman of the Board to replace Mr. Irwin.
- Investigation: The Audit Committee has commenced an independent investigation regarding an anonymous complaint and has retained independent counsel. The Company has notified the SEC of this investigation.
Outlook, Risks, and Contingencies
The Company faces significant uncertainty regarding the duration and outcome of the Audit Committee investigation, which is delaying the filing of its periodic reports. Forward-looking statements in the filing highlight risks related to:
- The potential discovery of additional information during the investigation.
- Delays in filing SEC reports and the review of financial statements by independent auditors.
- Challenges in characterizing and correcting issues with DABRA catheter manufacturing and performance.
- The success of cost-saving initiatives and the recruitment of a permanent CEO.
- Ongoing securities litigation and regulatory risks.
Investor Verification Checklist
- Verify the specific preliminary financial figures for the quarter ended June 30, 2019, in the press release attached as Exhibit 99.1.
- Monitor the status and findings of the Audit Committee's independent investigation regarding the anonymous complaint.
- Track the timeline for the filing of the delayed Form 10-Q.
- Review the progress of the search for a permanent Chief Executive Officer.
- Assess updates regarding the manufacturing and performance issues of the DABRA catheter.